Media
2023 ASH – Angel Pharmaceuticals to Present Latest Interim Data from Phase I/Ib Clinical Trial of Soquelitinib (ITK Inhibitor) in T-Cell Lymphomas
Jiaxing, China and Burlingame, Calif., U.S.A. – November 7, 2023 – Angel Pharmaceuticals, a clinical-stage innovative drug company, today announced that it will present updated interim data from its Phase I/Ib clinical trial of Soquelitinib (ITK inhibitor) in patients with refractory peripheral T-cell lymphomas at the 65th American Society of Hematology (ASH) Annual Meeting, to be held December 9–12, 2023. Details of the poster presentation will be available in the poster hall and on the virtual event platform, as follows:
Date and Time: Saturday, December 9, 2023, 5:30 PM PT
Title: Dynamic Single-Cell Sequencing Reveals Novel Immunomodulatory Mechanism of the ITK Inhibitor Soquelitinib in Refractory T-Cell Lymphomas
Abstract #: 1442
Presenter: Dr. Ding Ning, Peking University Cancer Hospital, Beijing, China
About Angel Pharmaceuticals
Angel Pharmaceuticals is an innovative drug company dedicated to oncology and autoimmune diseases. With the mission of benefiting Chinese patients, Angel is committed to bringing globally top-tier innovative drugs for serious diseases such as cancer and autoimmune disorders to China. In October 2020, Angel Pharmaceuticals completed its Series A financing round, co-invested by Beta Fund, Hisun Pharmaceuticals, Tigermed, and Puhua Investment, and established a strategic partnership with Corvus Pharmaceuticals (CRVS) of the U.S. For more information, please visit www.angelpharma.com.
About Soquelitinib
Soquelitinib (CPI-818) is an investigational oral small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T-cell kinase) in clinical studies. ITK is an enzyme expressed primarily on T cells and plays a role in T-cell and natural killer (NK) cell lymphomas and leukemias, as well as in normal immune function. The immune effects mediated by Soquelitinib result in Th1 skewing, and this effect is attributable to the high selectivity of Soquelitinib for ITK. Studies on the mechanism of action of Soquelitinib have shown its potential to control the differentiation of normal T helper cells and enhance immune responses by increasing the production of cytotoxic killer T cells and inhibiting the production of cytokines that support cancer cell survival. Soquelitinib has also been shown to prevent T-cell exhaustion, a major limitation of current immunotherapies and CAR-T therapies. It has been demonstrated that the optimal dose of Soquelitinib can influence T-cell differentiation, induce the production of Th1 helper cells, while blocking the development of Th2 and Th17 cells and the production of Th2-related cytokines. Th1 T cells are essential for tumor immunity, viral infections, and other infectious diseases. Th2 and Th17 helper T cells are involved in the pathogenesis of many autoimmune and allergic diseases. Angel Pharmaceuticals believes that inhibiting this specific molecular target in T cells may have therapeutic benefits for patients with cancers, including solid tumors, as well as those with autoimmune and allergic diseases. This is based on interim results from a Phase I/Ib clinical trial in patients with refractory T-cell lymphomas, which has demonstrated efficacy in a very advanced, relapsed/refractory T-cell malignancy population.
